A new educational unit named the SZTE-Egis Industrial Partnership Department will begin operations at the Faculty of Pharmacy of the University of Szeged (SZTE). Egis and the University of Szeged have already successfully collaborated in several areas as strategic partners, and the launch of the new department marks a milestone in their joint work. The agreement was ceremoniously signed on March 5, 2025, in Budapest, at the Egis Science and Technology Center.

Over the past four years, our company has made significant progress in the field of oncological active ingredient and preparation development, thanks to the support received through the project titled ´Development of innovative, high added value oncological drug preparations for personalized therapies.´ During the period from 2021 to 2024, we worked on the development of 14 active ingredients and 5 preparations in collaboration with our consortium partner, HUN-REN TTK.

he project identified as 2020-1.1.2-PIACI-KFI-2020-00039, conducted by Egis Pharmaceuticals PLC and its consortium partner, the HUN-REN Research Centre for Natural Sciences (TTK), finished on December 31, 2024.

Egis Pharmaceuticals Plc. applied for the prestigious Top Employer Hungary certification for the first time and successfully joined the ranks of companies recognized for their outstanding employer practices on an international level.

Egis Pharmaceuticals has announced that, backed by the Hungarian Competition Authority´s official certification, it has acquired one of Hungary´s well-known, locally applied dermatological product lines from Teva Pharmaceutical Industries Ltd. This move aims to strengthen Egis´s position in the Hungarian over-the-counter (OTC) market.

The Hungarian Innovation Association, in collaboration with the Hungarian Innovation Foundation, announced the contest for the 2024 Innovation Grand Prize at the Egis Science and Technology Center. The significance of the award is highlighted by the fact that innovative companies can apply for the 33rd time for the competition, which will conclude with a ceremonial award ceremony next spring.

Under the patronage of Márton Nagy, Minister of National Economy, the Hungarian Pharmaceutical Manufacturers Association (MAGYOSZ) held its annual conference, focusing on enhancing the competitiveness of the domestic and European pharmaceutical industry. In his speech, the minister emphasized that the pharmaceutical industry is a historical sector in Hungary and a crucial pillar of growth.

• mAbxience and Egis collaborate on the commercialization of two biosimilar candidates • The agreement covers eight Central and Eastern European countries with the potential for expansion into additional territories • mAbxience will serve as the marketing authorization holder, while Egis will manage commercialization in the designated regions

The red-black team of the Vas county town and one of the largest Hungarian pharmaceutical companies have extended their cooperation for another year. The team will continue to play under the name Egis Körmend in the championship.

In Hungary, industries closely related to chemistry – the chemical industry, pharmaceutical industry, and environmental industry – have significant national economic weight, yet these sectors face above-average labor shortages.

On the Night of Museums, our programme was quite a popular one: we had more than 120 visitors on this special night. The places were snapped up so quickly that after a few days, we had to close the registration.

Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize.